巴林顿生物疗法公司 plc ADR 2025年季度报告

QUARTERLYREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 (State or other jurisdiction ofincorporation or organization)Unit 6-10, Zeus Building,Rutherford Avenue, Harwell, Didcot,United Kingdom (Address of principal executive offices)(Zip Code)Registrant’stelephonenumber,includingareacode:+44 (0)1865 818 808SecuritiesregisteredpursuanttoSection12(b)oftheAct: Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).YesxNoo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Large accelerated fileroAccelerated fileroNon-accelerated filerxSmaller reporting companyx If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yeso NoxAs of May1, 2025, the registrant had40,339,395ordinary shares, nominal value £0.000025 per share, outstanding. Item 1.Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosure About Market Risk Unregistered Sales of Equity SecuritiesandUse of Proceeds Item 5.Other Information ExhibitsSIGNATURESWe own the registered trademark BARINTHUS in the United Kingdom, and we have filed applications at the U.K. IntellectualProperty Office and other intellectual properties to register trademarks for BARINTHUS, SNAP-TI, SNAP-CI and a design logoglobally. We also own various trademark registrations and applications, and unregistered trademarks, including the registered in December 2021 including the registered trademarks SNAPVAX and SYNTHOLYTIC. All other trade names, trademarks andservice marks of other companies appearing in this Quarterly Report on Form 10-Q, or this Quarterly Report, are the property of theirrespective holders. Solely for convenience, the trademarks and trade names in this Quarterly Report may be referred to without the ®and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullestextent under applicable law, their rights thereto. We do not intend to use or display other companies’ trademarks and trade names toimply a relationship with, or endorsement or sponsorship of us by, any other companies.From time to time, we may use our website, our X (formerly known as Twitter) account at @Barinthusbio and our LinkedIn account atlinkedin.com/company/barinthus-bio to distribute material information about us and for complying with our disclosure obligationsunder Regulation FD. Our financial and other material information is routinely posted to and accessible on the Investors section of ourwebsite, available at www.barinthusbio.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessedthrough our website, our X (formerly known as Twitter) posts and our LinkedIn posts are not incorporated into, and does not form apart of, this Quarterly Report.i Condensed Consolidated Financial Statements (Unaudited)Condensed Consolidated Balance Sheets Depreciation and amortizationNon-cash lease expenses Change in contingent considerationNon-cash interest expense Changes in operating assets and liabilities: Accounts payableAccrued expenses and other current liabilities (2,522)Deferred income(277)Operating lease liabilities(478)Net cash used in operating activities$(14,902)$(11,822) CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from issue of ordinary shares, net of issuance costs—Issue of shares from the exercise of stock options2Net cash provided by financing activities$2$ Cash, cash equivalents and restricted cash, beginning of the period112,400Cash, cash equivalents and restricted cash, end of the period$100,579$Supplemental cash flow disclosures:Non-cash investing and financing activities:Purchases of property and equipment included in accounts payable and accrued liabilities$—$Indicates amounts less than one thousand 1.Nature of Business and Basis of PresentationBarinthus Biotherapeutics plc is a public limited company incorporated pursuant to the laws of England and Wales in March 2021.BarinthusBiotherapeutics plc and its direct and indirect subsidiaries,Barinthus Biotherapeutics(UK)Limited,